appliedclinicaltrialsonline12h
SCOPE Summit 2025: Rajneesh Patil of IQVIA Highlights the Use of AI/ML in Improving Overall Cycle Times and Clinical Development
In an interview with ACT senior editor Andy Studna at SCOPE Summit, Patil, vice president, digital innovation, IQVIA, ...
appliedclinicaltrialsonline20h
SCOPE Summit 2025: Peter Ronco on the Risks Small Biopharma Companies Face in Clinical Trial Partnerships
In an interview with Applied Clinical Trials Associate Editor Don Tracy Peter Ronco, CEO, Emmes, discusses the number of ...
appliedclinicaltrialsonline14h
SCOPE Summit 2025 Panel Discussion: Balancing Innovation Options to Enable Adoption
Session explores innovation in operationalizing clinical trials and how challenges with adoption can be addressed.
appliedclinicaltrialsonline13h
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...